Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 CAD | 0.00% | -0.94% | -21.85% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.85% | 108M | |
+2.16% | 42.75B | |
+47.75% | 41.61B | |
+12.03% | 41.34B | |
-12.36% | 26.59B | |
+8.11% | 25.49B | |
-23.50% | 18.12B | |
+30.25% | 12.24B | |
-1.90% | 11.76B | |
+8.10% | 11B |
- Stock Market
- Equities
- NGEN Stock
- News NervGen Pharma Corp.
- NervGen Pharma Reports Dosing of All Subjects in Phase 1 Clinical Trial of Drug Candidate NVG-291